The Association of Alzheimer's Disease-related Blood-based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa

Megan **Schwinne**, M.P.H.[a,b], Alvaro **Alonso**, M.D., Ph.D.[b] Blaine R. **Roberts**, Ph.D.[c], Sabrina **Hickle**, Ph.D.[d], Inge MW **Verberk**, Ph.D.[e], Emmanuel **Epenge**, M.D.[f,g], Guy **Gikelekele**, M.D.[h], Nathan **Tsengele**, M.D.[h,i], Immaculee **Kavugho**, M.A.[j], Samuel **Mampunza**, M.D., Ph.D.[h], Kevin E. **Yarasheski**, Ph.D.[k], Charlotte E. **Teunissen**, Ph.D.[e], **Anthony Stringer**, Ph.D.[d], Allan **Levey**, M.D., Ph.D.[l], Jean **Ikanga**, Ph.D.[d,g]

a. Emory University School of Medicine, Department of Biomedical Informatics, Atlanta, GA, 30322, USA
b. Emory University Rollins School of Public Health, Department of Epidemiology, Atlanta, GA 30322, USA
c. Emory University, School of Medicine, Department of Biochemistry, Department of neurology, Atlanta, GA 30322, USA
d. Emory University School of Medicine, Department of Rehabilitation Medicine, Atlanta, GA 30322, USA
e. Amsterdam University Medical Centers, Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Neurodegeneration, Amsterdam University Medical Centers, Vrije Universitiet, 1081 HV Amsterdam, the Netherlands
f. University of Kinshasa and Catholic University of Congo, School of Medicine, Kinshasa, Department of Psychiatry, B.P. 7463 Kinshasa I, Democratic Republic of Congo
g. Protestant University of Congo, Kinshasa, B.P. 4745 Kinshasa II, Democratic Republic of Congo
h. University of Kinshasa, Department of Psychiatry, Kinshasa, B.P. 7463 Kinshasa I, Democratic Republic of Congo
i. University of Kikwit, Faculty of Medicine, Democratic Republic of Congo
j. Memory Clinic of Kinshasa, Kinshasa, B.P. 7463 Kinshasa I, Democratic Republic of Congo
k. C$_2$N Diagnostics, C$_2$N Diagnostics, Saint Louis, MO 63110, USA
l. Emory University School of Medicine, Department of Neurology, Atlanta, Georgia 30322, USA

***Corresponding author.** Please send general questions about the study to Dr. Jean Ikanga.
Jean N. Ikanga, Ph.D.
Department of Rehabilitation Medicine
Emory University
1441 Clifton Rd NE
Atlanta, GA 30322, USA
Email: jikanga@emory.edu
Office Phone: (404) 712-5667

Running Title: AD Biomarkers and Cognition in Congo

Abstract.

Background: Alzheimer's Disease (AD), the primary cause of dementia, poses a significant global burden. Diagnosis typically involves invasive and costly methods like neuroimaging or cerebrospinal fluid (CSF) biomarker testing of phosphorylated tau (p-tau) and amyloid-$\beta_{42/40}$ ($A\beta_{42/40}$). Such procedures are especially impractical in resource-constrained regions, such as the Democratic Republic of Congo (DRC). Blood-based biomarker testing may provide a more accessible screening opportunity.

Objective: This study aims to examine if AD-related blood-based biomarkers are associated with cognitive test performance in the Congolese population, where limited research has been conducted.

Methods: In this cross-sectional study of 81 Congolese individuals, cognitive assessments (Alzheimer's Questionnaire (AQ) and Community Screening Interview for Dementia (CSID)) distinguished dementia cases from controls. Blood draws were taken to assess p-tau 181 and $A\beta_{42/40}$ biomarkers. Relationships between the biomarkers and cognitive performance were analyzed using multiple linear regression models.

Results: Plasma $A\beta_{42/40}$ was significantly associated with lower CSID scores and higher AQ scores, indicative of AD ($p<0.001$). These relationships were observed in healthy controls (CSID $p=0.01$, AQ $p=0.03$), but not in dementia cases. However, p-tau 181 did not exhibit significant associations with either measure. Factors such as age, sex, education, presence of APOE e4 allele, did not alter these relationships.

Conclusion: Understanding relationships between AD-related screening tests and blood-biomarkers is a step towards utilization of blood-based biomarker tests as a screening tool for

65 AD, especially in resource-limited regions. Further research should be conducted to evaluate

66 blood biomarker test efficacy in larger samples and other populations.

68 **Keywords:** Alzheimer's Disease, amyloid-beta protein, biomarkers, blood-based biomarkers,

69 cognitive test, dementia, tau proteins

INTRODUCTION

Dementia, one of the top five causes of death globally, is an umbrella term encompassing

a group of characteristic symptoms, which include difficulties with memory, language, problem-

solving, and other thinking skills.[1,2] Alzheimer's Disease (AD), the leading cause of dementia in

individuals aged 65 or older, is a large global burden, with about 60 million people currently

living with dementia[1] and predicted to be over 150 million by 2050.[3,4] Dementia is a clinical

syndrome that does not require a diagnosis via biomarker measurements or PET-scans. However,

AD is diagnosed based on clinical symptoms of dementia along with a distinct biomarker profile

or PET-scan.[5] AD is a slowly progressive neurodegenerative disease characterized by cerebral

accumulation of amyloid plaques and neurofibrillary tangles.[4] The changes in the brain from AD,

such as the degeneration of nerve cells as well as the accumulation of the abnormal proteins,

beta-amyloid and phosphorylated tau, are contributors to dementia.[2] While the underlying cause

of these pathological changes in AD is still unknown, the predominant risk factor is aging, in

which the incidence is higher with increasing age with a late onset of 65 years or older. Genetic

factors also play a major role, with 70% of AD cases relating to genetics.[4] In fact, the e4 allele of

the apolipoprotein E (APOE) gene is the strongest genetic risk factor for AD and the APOE e2

allele is the strongest genetic protective factor.[6]

As AD risk increases with age, it is important to focus on the African population, since they are aging at an unprecedented rate.[2,7] This demographic transition is occurring faster in low and middle-income countries (LMIC) than it was in the previous century for high-income countries (HIC).[8] Thus, the largest proportion of the predicted increase in AD will take place in LMIC, especially East Asia and Sub-Saharan Africa, where over 70% of individuals with dementia are expected to live in 2040.[7,8]

Common measures to screen for AD and related dementias include the Alzheimer's Questionnaire (AQ) and the Community Screening Interview for Dementia (CSID). These measures combine a short cognitive screener with information from close contacts regarding daily functioning; the combination of the two types of tests yields better sensitivity and specificity for dementia diagnosis.[9] While the two screening tools have some different cognitive domains being tested, they both encompass semantic, executive, and memory knowledge.[10] Since both assessments have different attributes that may be advantageous to different populations, it is important to utilize multiple screening tools and supplementary tactics to identify cases of AD.

Given that neurodegenerative diseases, such as AD, are difficult to diagnose clinically, characteristic biomarkers of AD, such as total tau (T-tau), phosphorylated tau (p-tau), amyloid-β_{42} (Aβ_{42}), and amyloid-β_{40} (Aβ_{40}), are important for research and early diagnosis.[11,12] Increased levels of T-tau and p-tau with decreased Aβ_{42} in cerebrospinal fluid (CSF) is the biomarker pattern known as the "Alzheimer's CSF Profile", as they reflect key elements of AD pathophysiology.[13] Tau protein normally binds to and stabilizes the neuronal microtubules but hyperphosphorylation disrupts the microtubules, impairs the plasma and axon flow, and leads to loss of neuronal connectivity.[13] A lower Aβ_{42} reflects aggregation and deposition of protein in the brain. Aβ_{40} is the most abundant variant of Aβ in CSF, so the A$\beta_{42/40}$ ratio is utilized to

compensate for inter-individual differences in amyloid precursor protein (APP) expression and

processing that can result in different but proportional concentrations of the CSF and plasma Aβ

peptides. As such, the Aβ$_{42/40}$ ratio is a better predictor of the presence of brain amyloid plaques

than the plasma concentrations alone.[13,14,15] Low CSF and plasma Aβ$_{42/40}$ ratios and high tau

concentrations are fluid biomarkers for AD pathology [13]Although obtaining the biomarkers via

CSF has been customary practice, obtaining the biomarkers from blood is more accessible than

CSF and is preferable for both screening and sampling purposes.[13] While there are several

caveats making blood more challenging than CSF for brain biomarkers, such as dilution with

other plasma proteins and degradation by proteases in the blood, novel developments in

ultrasensitive immunoassays as well as mass spectrometry bring promising results for the use of

blood biomarkers over CSF biomarkers.[13]

Substantial research has been implemented to demonstrate the use of cognitive tests as

well as CSF biomarkers, such as Aβ$_{42/40}$ and p-tau 181, to screen for AD; however, current

research on the association between AD diagnosis and these biomarkers in blood has been

predominantly limited to studies conducted in high-income countries. Very few studies have

occurred in Sub-Saharan Africa, specifically in the DRC[7,8]. Given the invasiveness and expense

of retrieving biomarkers via CSF, it is critical to determine other plausible screening methods to

evaluate individuals for AD. Furthermore, with the increasing prevalence of AD in LMIC, in

specific Africa, it is important to focus research on these populations, especially since the

majority of AD-related research is conducted in populations of European ancestry and in high-

income countries. This study aims to evaluate the association between AD-related plasma

biomarkers with the cognitive tests, CSID and AQ, in a cohort from Sub-Saharan Africa.

METHODS

Study Design and Participants

From 2019 to 2022, a cross-sectional study using community-based recruitment was

carried out in Kinshasa, the capital of the Democratic Republic of Congo (DRC). 1432

individuals were recruited from churches, clinics, hospitals, door-to-door, and older adult

associations to then be screened. Eligibility criteria required that participants are 50 years or

older, have a close contact to serve as a collateral informant, have no current or past history of

neurodevelopmental, mental, psychiatric, or neurogenerative diagnosis other than dementia, able

to give informed consent, fluent in French or Lingala, and have adequate sensory perceptual

skills to be able to see and draw for cognitive tests. Cognitive test data was collected between

2019-2021 and blood specimens for biomarker analysis were collected between 2021-2022. Only

some participants, less than those who had cognitive tests, were given the option to proceed with

donating blood specimens. The enrollment flowchart is presented in Figure 1. This study was

approved by the Ethics Committee and Institutional Review Boards of the University of

Kinshasa and written informed consent was obtained from participants as well as financial

compensation.

Figure 1. Flow Chart of Recruitment Status from those assessed for eligibility at enrollment (n=1432)
to the individuals that were allocated to the dementia or control group and analyzed (n=81)
150

Cognitive Measurements

Participants and their informants were administered the CSID as well as the AQ test to

screen for dementia and to be further assigned into the dementia group or the healthy control

group, which comprised of individuals with normal cognitive aging. The CSID, a 42-question

screening measure, provides a score ranging from 0 to 55, with a lower score indicating worse

cognition. As a widely accepted dementia screening tool to use cross-culturally, it serves to

detect dementia in various populations with diverse educational, cultural, and linguistic

identities.[7,9] While this instrument is not the gold standard for diagnosis, it has been used in

developing countries when higher quality screening instruments are not available. It evaluates

the cognitive domains of language and expression, memory, learning, attention and calculation,

praxis, orientation in space and time, and language comprehension. The AQ, an informant-only

questionnaire, is 21-questions, with a score ranging from 0 to 26; a higher score indicates worse

cognition. It is advantageous in providing questions that require yes or no answers in a weighted

format, requiring no interpretation for individual components of the test.[10] This assessment

evaluates the memory, orientation, functional ability, visuospatial, and language domains.

Participants were first classified using CSID scores as cognitively impaired (CSID score of $<$

25.5) or as cognitively unimpaired (CSID score of $\geq$ 25.5). Next, participants were classified

within each category of cognition via AQ scores as cognitively impaired (AQ score of $>$ 13) or

as cognitively unimpaired (AQ score of $\leq$ 13). Given the two cognitive tests and classifications,

4 separate groups were created, which were major neurocognitive disorder (CSID $<$ 25.5 and AQ

$>$ 13), mild neurocognitive disorder (CSID $<$ 25.5 and AQ $\leq$ 13), subjective cognitive

impairment (CSID $\geq$ 25.5 and AQ $>$ 13), and normal cognition (CSID $\geq$ 25.5 and AQ $\leq$ 13),

following DSM-IV terminology. Only the individuals with major neurocognitive disorder, which

were considered to have dementia, and the individuals with normal cognition, which were

considered healthy controls, were included for this analysis. Out of the 1432 initial participants,

271 met the above criteria for major neurocognitive disorder or normal cognition, in which 88

individuals were classified as having major neurocognitive disorder and 183 individuals were

classified as healthy subjects with normal cognition. Following this classification, an expert

panel of neuropsychologists, neurologists, and psychiatrists further evaluated the individuals

through neurological and psychiatric evaluations, as well as assessing medical history. They then

confirmed 55 individuals to have major neurocognitive disorder and then matched 59 healthy

controls on age, education, and sex (Figure 1). Due to the participants not having PET-scans or

CSF biomarker tests in this study, participants with major neurocognitive disorder will be

characterized as having dementia and will not be identified as individuals with possible AD.[5]

Descriptive Measurements

Participants were given self-report questionnaires and interviews to obtain demographic,

socioeconomic, and medical history information. Individuals were categorized into age groups of

50-64, 65-74, 75-84, and 85+. Education levels were also categorized into levels of primary

school (1-6 years), secondary school (7-12 years), some or completion of university (13-17

years), and beyond university (18+ years). Medical residents measured hypertension by using a

manual sphygmomanometer and three measurements of systolic and diastolic blood pressure

were collected. Having an average systolic blood pressure over 140 mmHg or a diastolic blood

pressure over 90 mmHg was defined as hypertension.

Biomarker Measurements

For the individuals that consented to blood donation for blood biomarker measurements,

a phlebotomist drew the blood at the Medical Center of Kinshasa (CMK) blood laboratory by

venipuncture into ethylenediaminetetraacetic acid (EDTA) tubes. Blood samples were

centrifuged within 15 minutes and 5 ml plasma were aliquoted into 0.5 ml tubes. The samples

were temporarily stored at -20 $^\circ$ Celsius for less than a week and then at -80 $^\circ$ C for longer-term

storage at the CMK laboratory freezer. The samples were then shipped on dry ice to Emory

University laboratory and analyzed by C_2N Diagnostics ($A\beta_{42}$ and $A\beta_{40}$ peptides) and by Dr.

Blaine Roberts's lab at Emory University (p-tau 181). For the $A\beta_{42/40}$ ratios, plasma samples

were spiked with stable isotope labeled recombinant proteins. Plasma proteins were extracted

using proprietary antibodies conjugated to magnetic beads, eluted from the beads, and then

digested with a site-specific protease to form C-terminal peptides specific to $A\beta_{42}$ and $A\beta_{40}$

proteins. The peptides were separated using micro-flow liquid chromatography and electro-

sprayed into the source of a high resolution orbitrap mass spectrometer. This procedure identifies

the peptides of interest based on known amino acid sequence and mass to charge ratio. It then

quantifies the ion signal intensity from the endogenous peptides by comparison to a calibration

curve created with a stable isotope labeled internal standard peptide. The $A\beta_{40}$ and $A\beta_{42}$

concentrations were quantified by comparing the signal intensities for the endogenous peptides

to those obtained from the stable isotope labeled proteins spiked into the sample. $A\beta_{42/40}$

concentration ratios were calculated as plasma $A\beta_{42}$ (pg/mL)/$A\beta_{40}$ (pg/mL). To analyze p-tau 181

concentrations, EDTA plasma samples were prepared according to manufacturer's instructions

from the p-tau 181 kit v2 (Quanterix Billerica, Massachusetts, USA). Samples were run in a

single path. Plasma was thawed at room temperature for 45 minutes and then centrifuged at

5000xg for 10 minutes. The plasma samples were then diluted four times on bench and measured

on the Simoa HDX platform. Mean intraassay coefficients of variation (CV) were below 10%.

Statistical Analysis

Of the study population, 81 individuals had both biomarker and cognitive data (43

dementia cases and 38 healthy controls, Figure 1). Preliminary analysis involved obtaining

frequencies and means of sex, age, education level, and basic medical history, for the overall

sample population and the two groups of differing neurological status separately. Multiple linear

regression models were utilized to analyze associations between cognitive test scores (dependent

variable) and blood biomarkers (main independent variable). Neurological status was also a

primary indicator variable in a model analyzing associations between cognitive tests or blood

biomarkers with status. Analyses considered the overall CSID and AQ scores, as well as domain-

specific scores (executive, semantic, and memory) separately. The biomarkers evaluated were

plasma p-tau 181 and $A\beta_{42/40}$ values. These models analyzed associations overall as well as

stratified by neurological status (dementia or healthy control). $A\beta_{42/40}$ was modeled in 0.01

increments, its standard deviation, to represent more meaningful findings in relation to

associations with cognitive test scores. All models controlled for age, sex, and education, as

these covariates may be possible confounders and bias the measures of association. The results

were expressed as β-coefficients with corresponding 95% confidence intervals. Tests for

potential interactions between biomarkers and covariates, including sex, age, education, and

APOE status were conducted to understand if these variables significantly affected the

relationship between biomarkers and cognitive tests. Tests for interaction involving the variables

age and education were assessed on a continuous scale. The presence of the e4 allele in APOE

genotypes, a known risk factor for AD, was assessed as a categorical variable, in which

individuals were dichotomized as either having the e4 allele or not.[6] All statistical tests were

two-sided, and p-values < 0.05 were considered to be statistically significant. All analyses were

conducted using SAS version 9.4 statistical software.

RESULTS

Descriptive and Clinical Characteristics of the Sample Population

Baseline characteristics of the 81 individuals, including demographics and medical

history, were reported in Table 1. The sample population consisted of 43 dementia cases and 38

healthy controls with a mean age of 73 years (ranging from 50-88 years old). Sex, body mass

index, age groups, and education levels were similar between the dementia and control groups,

confirming matching was performed appropriately. Regarding medical history, a large proportion

of the participants (53%) had hypertension, with more dementia cases having prevalent

hypertension compared to the controls (60% and 45% respectively). Additionally, more of the

dementia cases (28%) reported alcohol abuse compared to the control group (11%). The

remaining relevant medical history and mental conditions, such as high cholesterol, poor

nutrition, anxiety, and depression were minimally reported among the sample.

Table 1. Descriptive Characteristics of the Sample Population, Stratified by Neurological Status

Variable, n (%)	Healthy Controls (n = 38)	Dementia Cases (n = 43)	Overall (n = 81)
Demographics			
Male	16 (42%)	19 (44%)	35 (43%)
Body Mass index, kg/m^2 *	24.6 (4.1)	24.8 (4.4)	24.7 (4.3)
Age, years *	71.7 (7.9)	74.0 (8.1)	73.0 (8.0)
Age Groups, years			
50-64	6 (16%)	5 (12%)	11 (14%)
65-74	16 (42%)	13 (30%)	29 (36%)
75-84	16 (42%)	21 (49%)	37 (46%)
85+	0 (0%)	4 (9%)	4 (5%)
Years of Education *	9.2 (5.3)	7.3 (5.5)	8.2 (5.4)
Education Level			
Primary School (1-6 years)	2 (5%)	6 (14%)	8 (10%)
Secondary School (7-12 years)	12 (32%)	16 (37%)	28 (35%)
Some/Completed University (13-17 years)	14 (37%)	13 (30%)	27 (33%)
Beyond University (18+ years)	10 (26%)	8 (19%)	18 (22%)
APOE e4			
Presence of ≥ 1 e4 Allele †	21 (26%)	19 (24%)	40 (50%)
e2/e4 Genotype	0 (0%)	2 (3%)	2 (3%)
e3/e4 Genotype	17 (21%)	13 (16%)	30 (38%)
e4/e4 Genotype	4 (5%)	4 (5%)	8 (10%)
Medical History			
Hypertension	17 (45%)	26 (60%)	43 (53%)
High Cholesterol	1 (3%)	1 (2%)	2 (2%)
Poor Nutrition	0 (0%)	1 (2%)	1 (1%)
Stroke	0 (0%)	2 (5%)	2 (2%)
Tobacco Abuse	5 (13%)	4 (9%)	9 (11%)
Alcohol Abuse	4 (11%)	12 (28%)	16 (20%)
Anxiety	2 (5%)	3 (7%)	5 (6%)
Depression	2 (5%)	5 (12%)	7 (9%)

251   *This variable is reported as mean (SD)

252   †These values may not sum to the total due to missing data

Descriptive Characteristics of Cognitive Tests

Upon comparison of CSID and AQ cognitive test scores between dementia cases and

healthy controls (Table 2), all overall scores as well as the semantic, executive, and memory

domain scores were significantly different between the two groups ($p < 0.01$). Given that the

higher the CSID score, the better the cognition, on average, the healthy controls scored higher in

all CSID domains compared to the dementia cases. The CSID memory domain had the largest

difference between groups and the CSID semantic domain scores were the least impacted.

Furthermore, the healthy control group scored lower on the AQ cognitive test compared to the

dementia cases. Again, the AQ memory domain yielded the largest difference and the AQ

semantic domain scores yielded the smallest difference between groups.

Table 2. Descriptive Data of Cognitive Tests and Biomarkers, stratified by Neurological Status

Variable, Mean (SD)	Controls (n = 38)	Dementia (n = 43)	Overall (n = 81)	β_1 (95% CI) *	p-value
Cognitive Tests					
CSID					
Overall Score	31.1 (4.2)	19.7 (5.6)	25.0 (7.6)	-11.0 (-13.2, -8.8)	<.001
CSID Semantic Domain Score	9.9 (0.3)	8.7 (1.8)	9.3 (1.5)	-1.2 (-1.8, -0.6)	0.003
CSID Executive Domain Score	14.9 (2.0)	10.0 (3.8)	12.3 (3.9)	-4.6 (-6.0, -3.3)	<.001
CSID Memory Domain Score	20.7 (4.3)	10.6 (5.1)	15.3 (6.9)	-9.9 (-12.0, -7.8)	<.001
AQ Test					
Overall Score	4.3 (5.4)	19.1 (3.9)	12.1 (8.8)	14.7 (12.6, 16.9)	<.001
AQ Semantic Domain Score	0.2 (1.0)	2.3 (1.7)	1.3 (1.7)	2.0 (1.4, 2.7)	<.001
AQ Executive Domain Score	1.4 (1.7)	6.3 (1.8)	4.0 (3.0)	4.8 (4.0, 5.6)	<.001
AQ Memory Domain Score	2.7 (3.0)	10.4 (2.7)	6.8 (4.8)	7.8 (6.5, 9.1)	<.001
Blood Biomarkers					
$A\beta_{42/40}$	0.106 (0.009)	0.099 (0.008)	0.102 (0.009)	-0.006 (-0.009, -0.002)	0.002
$A\beta_{42}$, pg/ml	51.0 (10.8)	47.8 (11.8)	49.3 (11.4)	-3.8 (-8.9, 1.4)	0.152
$A\beta_{40}$, pg/ml	486.0 (105.1)	483.4 (117.0)	484.6 (111.0)	-11.7 (-62.5, 39.0)	0.647
p-tau 181, ng/ml	1.5 (1.4)	1.6 (1.4)	1.6 (1.4)	0.02 (-0.6, 0.7)	0.939

265   *Results from linear regression models are adjusted for age, sex, and education.

Descriptive Characteristics of Blood Biomarkers

Average, $A\beta_{40}$, $A\beta_{42}$, $A\beta_{42/40}$ ratio, and p-tau 181 measures are also presented in Table 2.

$A\beta_{42/40}$ was significantly higher in the control group compared to the dementia group (p=0.002).

$A\beta_{40}$ and $A\beta_{42}$ were not significantly different between groups, but the ratio is most clinically

relevant as a biomarker for AD pathology. While $A\beta_{42/40}$ was significantly different, analysis of

p-tau 181 yielded essentially identical concentrations between the two groups of differing

neurological statuses (p=0.94).

Table 3. Assessing Interaction between Biomarkers and Covariates

Test	Biomarker	p-value for Interaction			
		Age	**Sex**	**Education**	**APOE e4 Allele**
CSID Total Score	p-tau 181, ng/ml	0.57	0.10	0.17	0.18
	$A\beta_{42/40}$ ⱡ	0.76	0.43	0.41	0.27
Overall AQ Score	p-tau 181, ng/ml	0.80	0.21	0.30	0.18
	$A\beta_{42/40}$ ⱡ	0.45	0.24	0.33	0.07

275 ⱡ $A\beta_{42/40}$ is modeled in 0.01 increments.

Association between Cognitive Tests and Biomarkers

Upon exploration of potential associations between blood biomarkers and cognitive test

scores among the whole study population, $A\beta_{42/40}$ was strongly associated with both CSID and

AQ overall scores (p<0.001), while p-tau 181 was not. CSID overall scores and $A\beta_{42/40}$

demonstrated a positive association while AQ overall scores and $A\beta_{42/40}$ demonstrated a negative

association. For every 0.01 increase in $A\beta_{42/40}$, on average the CSID overall score was 3.77

points higher, after adjusting for age, sex, and education. Furthermore, for every 0.01 increase in

$A\beta_{42/40}$, on average the AQ overall score was 4.58 points lower (a cognitively better score) after

adjustment. $A\beta_{42/40}$ was only significantly associated with the CSID test (p=0.01) and the AQ test

(p=0.03) among the healthy controls and not among the individuals with dementia (Table 4).

Potential interaction between biomarkers with covariates, including sex, age, education, and

APOE status was assessed. The test for interactions between these variables all resulted in p-

values > 0.05, meaning interaction was not present and these variables did not modify the

relationship between cognitive tests and biomarkers.

Table 4. Association Between Cognitive Tests and Biomarkers, Overall and Stratified by Neurological
Status

Test	Biomarker	Population	β_1 (95% CI) *	p-value
Overall CSID Score	p-tau 181, pg/ml	Overall	-0.63 (-1.99, 0.73)	0.36
		Dementia	-0.95 (-2.44, 0.53)	0.20
		Controls	-0.50 (-1.73, 0.74)	0.42
	$A\beta_{42/40}$ ɨ	Overall	3.77 (1.96, 5.58)	<.001
		Dementia	1.89 (0.68, 4.44)	0.14
		Controls	2.08 (0.62, 3.54)	0.01
Overall AQ Score	p-tau 181, pg/ml	Overall	0.97 (-0.65, 2.58)	0.23
		Dementia	0.92 (-0.18, 2.02)	0.10
		Controls	1.01 (-0.63, 2.65)	0.22
	$A\beta_{42/40}$ ɨ	Overall	-4.58 (-6.73, -2.43)	<.001
		Dementia	-1.37 (-3.32, 0.59)	0.17
		Controls	-2.24 (-4.28, -0.20)	0.03

293 *Results from linear regression models are adjusted for age, sex, and education.
294 ɨ $A\beta_{42/40}$ is modeled in 0.01 increments.
295

Cognitive tests were also stratified into their 3 domains, semantic, executive, and

memory function (Table 5). Only the CSID semantic domain was associated with p-tau 181

(p=0.03), while all other domains were not significantly associated with this biomarker.

However, all cognitive test domains were associated with $A\beta_{42/40}$ (p≤0.001) except for the CSID

semantic domain. For both the CSID and AQ tests, the memory domain had the strongest

difference by 0.01 $A\beta_{42/40}$ increments (3.47 and -2.4 respectively), while the semantic domain

had the smallest rate of change (0.38 and -0.78 respectively).

Table 5. Association Between Cognitive Test Domains and Biomarkers

Test	p-tau 181, ng/ml		$A\beta_{42/40}$ ɫ	
	β_1 (95% CI) *	p-value	β_1 (95% CI) *	p-value
CSID				
Overall Score	-0.63 (-2.0, 0.7)	0.36	3.77 (2.0, 5.6)	<.001
Semantic Domain Score	-0.30 (-0.6, -0.02)	0.03	0.38 (-0.01, 0.8)	0.06
Executive Domain Score	-0.51 (-1.2, 0.2)	0.15	1.78 (0.9, 2.7)	<.001
Memory Domain Score	-0.20 (-1.5, 1.1)	0.75	3.47 (1.8, 5.1)	<.001
AQ				
Overall Score	0.97 (-0.6, 2.6)	0.23	-4.58 (-6.7, -2.4)	<.001
Semantic Domain Score	0.20 (-0.1, 0.5)	0.23	-0.78 (-1.2, -0.3)	<.001
Executive Domain Score	0.29 (-0.3, 0.8)	0.29	-1.27 (-2.0, -0.5)	0.001
Memory Domain Score	0.39 (-0.5, 1.3)	0.39	-2.4 (-3.7, -1.2)	<.001

305 *Results from linear regression models are adjusted for age, sex, and education.

306 ɫ $A\beta_{42/40}$ is modeled in 0.01 increments.

DISCUSSION

Major Findings

In a community-based sample from the DRC, we found associations of blood $A\beta_{42/40}$ with

CSID and AQ scores, with lower $A\beta_{42/40}$ correlating with a lower CSID score and higher AQ

score, which is characteristic of AD and other dementias. These relationships were present for

healthy controls but not participants with dementia. However, circulating p-tau 181 was not

associated with either cognitive test. Age, sex, education, and presence of the APOE e4 allele,

which are known risk factor for AD, did not significantly modify these associations.

Previous research suggests that the use of biomarkers alongside neurocognitive tests is

the future of clinical practice, as they aid in early identification of AD and potential for

prevention of dementia manifestation or progression.[3] The literature has repeatedly shown that

reduced $A\beta_{42/40}$ and increased p-tau is characteristic of AD, and these relationships have

commonly been seen in CSF and more recently studied in blood.[13,15] Plasma $A\beta_{42/40}$ had similar

results with CSF tests, however, p-tau did not align as clearly and showed a weaker

relationship.[16] This supports these present findings since $A\beta_{42/40}$ was associated with tests

displaying cognitive impairment in multiple domains, but p-tau was not. With that said, a recent

study investigating associations between these plasma biomarkers and their relationship with

AD-associated neuroimaging results show that both biomarkers are significantly associated with

AD.[17]

Memory significantly differs among those with dementia most likely due to

pathophysiological changes, such as the accumulation of amyloid-beta and the development of

hyperphosphorylated tau protein tangles.[3] This then leads to secretion of neurotoxins and

inflammatory factors, resulting in neuronal death in specific brain areas and causes memory

impairment.

$A\beta_{42/40}$'s apparent association compared to p-tau 181's insignificant association with

cognitive status may be due to the differences in pathophysiological processes between the

biomarkers. $A\beta_{42/40}$ is an early, pre-symptomatic index for increased neurotoxicity,

amyloidogenicity, as well as disease severity, whereas p-tau 181 may be a more delayed,

symptomatic index for tau hyperphosphorylation, neurofibrillary tangles formation, and

degenerative axonal loss in the brain.[17] These processes may manifest differently in blood

samples compared to CSF samples, differ between individuals, or differ by the tau

phosphorylation site (p-tau181, 217, 231, etc.) measured, since the sites may have slightly

different temporal patterns over the disease course. It is interesting to note that an earlier study

among predominantly asymptomatic African Americans showed that plasma $A\beta_{42/40}$ measures

were more highly correlated with brain amyloid status (PET and CSF) than the p-tau 181

biomarker.[18] The findings from the current DRC cohort, support this observation, and suggest the

possibility that plasma tau biomarkers may need to be interpreted differently in people of African

descent vs. non-Hispanic Caucasians. It is also possible that the lack of association between p-tau

181 and cognitive status in this study was due to the small sample size and may not represent a

true finding.

While blood is cheaper, less invasive, and more accessible to sample from individuals

compared to CSF, there are inevitable caveats to blood biomarker analysis.[19] It is more difficult

to reliably measure blood biomarkers that are related to cognitive disorders because the

biomarkers are present at lower concentrations in the blood compared to CSF, which is closer to

the brain and allows for a free exchange of molecules.[13,16, 20] Only a fraction of brain proteins

enters the blood stream and biomarker dilution from peripheral sources may occur. Brain

proteins released in the blood may be degraded by proteases or metabolized in the liver, leading

to potential for varying measurements that may not necessarily be representative of brain or CSF

biomarker levels, and thus, cognitive impairment. Lastly, the low levels of brain proteins

entering the blood are mixed in a matrix containing high levels of unrelated plasma proteins that

need to be cleared from the plasma during sample preparation and may skew results.[13]

Nevertheless, advancements in technology have aided in showing the feasibility of measuring

blood-based biomarkers more accurately and with clinically meaningful results.

Strengths and Limitations

This study had numerous strengths through the study design, setting, and statistical

analyses methods. First, Sub-Saharan Africa, specifically the DRC, is an understudied area for

dementia and AD, therefore this research strengthens and adds to knowledge of AD and its

associated biomarkers for this population. The research staff were also familiar with the area and

the population of interest so there was enhanced partnership and no language barrier. Third, the

sample was relatively healthy and varied in age, sex, and education levels. Furthermore, multiple

cognitive tests (CSID and AQ) as well as an expert panel were utilized to establish and confirm

the participants cognitive ability to prevent misclassification. Additionally, dementia cases and

healthy controls were matched on age, sex, and education as part of the study design, but these

covariates were also controlled for in analysis, decreasing the possibility of confounding. Lastly,

statistical tests prevented further potential bias by confirming there were no outliers or key

variables causing interaction.

As with all research studies, there are inevitably limitations. While Sub-Saharan Africa,

specifically the DRC is an understudied area, the population within the region lacks variability in

race and ethnicity, so there is lack of generalizability to other populations. Additionally, given

the location, it is a complicated setting with less access to advanced technology. Variables that

may have been risk factors or confounders, such as physical activity and family history were not

considered and the sample size of 81 is rather low, decreasing the statistical power. Lastly, there

was a discrepancy in the number of questions in this study's CSID test compared to the most

common CSID test (36 vs. 42 questions), which decreases comparability.

Conclusions

Understanding the AD-specific blood biomarkers $A\beta_{42/40}$ and p-tau 181 relationships with

neurocognitive tests related to AD is a promising next step in the implementation of blood-based

biomarkers in order to overcome access and cost barriers, especially in LMIC. Instruments for

quantifying blood biomarkers are becoming more sensitive and implementation is increasing.

While blood biomarkers are not equivalent to an AD diagnosis yet, they can be utilized as a

screening tool before resorting to PET-scan neuroimaging or CSF biomarker analysis. Future

studies are needed in which AD-related blood and CSF biomarkers are tested longitudinally from

the same individuals for better comparison and further validation. Additionally, larger studies

with greater sample sizes and diversity in races and ethnicities should be employed to increase

global generalizability.

ACKNOWLEDGEMENTS

The authors acknowledged the expertise from the Centre Médical de Kinshasa (CMK), who have

assisted our study with blood specimen collection, as well as C2N Diagnostics Laboratory for

support in plasma biomarker analysis. Additionally, the authors thank Emory Rollins School of

Public Health for guidance with data processing and analysis. Furthermore, this research is

Supported by the National Center for Advancing Translational Sciences of the National Institutes

of Health under Award # UL1TR002378. The content is solely the responsibility of the authors

and does not necessarily represent the official views of the National Institutes of Health.

FUNDING

This study was supported by grants AARG-19-61778701 and P30AG066511-02S1 from the

National Institute on Aging. Dr. Alonso was supported by NIH/NHLBI grant K24HL148521 and

NIH/NIA grant P30AG066511. Dr. Daniel Drane and the neuroimaging analysis efforts were

funded by the NIH/NINDS through grant R01 NS088748. C$_2$N Diagnostics analyses were

supported by the NIH (grant No. R44 AG059489), BrightFocus (grant No. CA2016636), The

Gerald and Henrietta Rauenhorst Foundation, and the Alzheimer's Drug Discovery Foundation

(grant No. GC-201711-2013978).

CONFLICT OF INTEREST

405 KEY is employed by and receives equity compensation from C$_2$N Diagnostics, LLC. All other

406 authors have no conflict of interest to report.

DATA AVAILABILITY

408 The data supporting the findings of this study are available on request from the corresponding

409 author. The data are not publicly available due to privacy or ethical reasons.

REFERENCES

[1] Collaborators, G. D. F. (2022). Estimation of the global prevalence of dementia in 2019
and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study
2019. Lancet Public Health, 7(2), e105-e125. https://doi.org/10.1016/S2468-
2667(21)00249-8
[2] 2022 Alzheimer's disease facts and figures. (2022). Alzheimers Dement, 18(4), 700-789.
https://doi.org/10.1002/alz.12638
[3] Tahami Monfared, A. A., Byrnes, M. J., White, L. A., & Zhang, Q. (2022). Alzheimer's
Disease: Epidemiology and Clinical Progression. Neurol Ther, 11(2), 553-569.
https://doi.org/10.1007/s40120-022-00338-8
[4] Breijyeh, Z., & Karaman, R. (2020). Comprehensive Review on Alzheimer's Disease:
Causes and Treatment. Molecules, 25(24). https://doi.org/10.3390/molecules25245789
[5] Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., . . .
Feldman, H. H. (2021). Clinical diagnosis of Alzheimer's disease: recommendations of
the International Working Group. Lancet Neurol, 20(6), 484-496.
https://doi.org/10.1016/S1474-4422(21)00066-1
[6] Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021). APOE and Alzheimer's disease:
advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol, 20(1),
68-80. https://doi.org/10.1016/S1474-4422(20)30412-9
[7] Samba, H., Guerchet, M., Ndamba-Bandzouzi, B., Mbelesso, P., Lacroix, P., Dartigues, J.
F., & Preux, P. M. (2016). Dementia-associated mortality and its predictors among older
adults in sub-Saharan Africa: results from a 2-year follow-up in Congo (the EPIDEMCA-
FU study). Age Ageing, 45(5), 681-687. https://doi.org/10.1093/ageing/afw097
[8] Guerchet, M., Mbelesso, P., Ndamba-Bandzouzi, B., Pilleron, S., Desormais, I., Lacroix,
P., . . . group, E. (2014). Epidemiology of dementia in Central Africa (EPIDEMCA):
protocol for a multicentre population-based study in rural and urban areas of the Central
African Republic and the Republic of Congo. Springerplus, 3, 338.
https://doi.org/10.1186/2193-1801-3-338
[9] Hall, K. S., Gao, S., Emsley, C. L., Ogunniyi, A. O., Morgan, O., & Hendrie, H. C.
(2000). Community screening interview for dementia (CSI 'D'); performance in five
disparate study sites. Int J Geriatr Psychiatry, 15(6), 521-531.
https://doi.org/10.1002/1099-1166(200006)15:6<521::aid-gps182>3.0.co;2-f
[10] Sabbagh, M. N., Malek-Ahmadi, M., Kataria, R., Belden, C. M., Connor, D. J.,
Pearson, C., . . . Singh, U. (2010). The Alzheimer's questionnaire: a proof of concept

study for a new informant-based dementia assessment. J Alzheimers Dis, 22(3), 1015-1021. https://doi.org/10.3233/JAD-2010-101185

[11]   Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., . . . Zetterberg, H. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol, 15(7), 673-684. https://doi.org/10.1016/S1474-4422(16)00070-3

[12]   Leuzy, A., Mattsson-Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022). Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med, 14(1), e14408. https://doi.org/10.15252/emmm.202114408

[13]   Blennow, K., & Zetterberg, H. (2018). Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med, 284(6), 643-663. https://doi.org/10.1111/joim.12816

[14]   Barthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., . . . Schindler, S. E. (2023). CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. Nat Aging, 3(4), 391-401. https://doi.org/10.1038/s43587-023-00380-7

[15]   Hu, Y., Kirmess, K. M., Meyer, M. R., Rabinovici, G. D., Gatsonis, C., Siegel, B. A., . . . West, T. (2022). Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. JAMA Netw Open, 5(4), e228392. https://doi.org/10.1001/jamanetworkopen.2022.8392

[16]   Zetterberg, H., & Burnham, S. C. (2019). Blood-based molecular biomarkers for Alzheimer's disease. Mol Brain, 12(1), 26. https://doi.org/10.1186/s13041-019-0448-1

[17]   Chong, J. R., Ashton, N. J., Karikari, T. K., Tanaka, T., Saridin, F. N., Reilhac, A., . . . Chen, C. P. (2021). Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. Alzheimers Dement, 17(10), 1649-1662. https://doi.org/10.1002/alz.12332

[18]   Schindler, S. E., Karikari, T. K., Ashton, N. J., Henson, R. L., Yarasheski, K. E., West, T., . . . Morris, J. C. (2022). Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. Neurology, 99(3), e245-e257. https://doi.org/10.1212/WNL.0000000000200358

[19]   O'Bryant, S. E., Gupta, V., Henriksen, K., Edwards, M., Jeromin, A., Lista, S., . . . groups, S.-B. a. B. w. (2015). Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement, 11(5), 549-560. https://doi.org/10.1016/j.jalz.2014.08.099

[20]   Andreasson, U., Blennow, K., & Zetterberg, H. (2016). Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement (Amst), 3, 98-102. https://doi.org/10.1016/j.dadm.2016.05.005